Biodesix, a provider of personalizing medicine, has received three additional patents for its blood-based oncology tests.
Biodesix received two new patents from the US Patent & Trademark Office (PTO) which provides intellectual property protection for methods relating to its products and technology.
US patent number 8,024,282 (‘282) provides additional intellectual property protection for the methods used with VeriStrat which are also related to Biodesix’ underlying core ProTS technology.
Biodesix has also received a European Patent providing coverage for its VeriStrat product for the selection of patients for drug therapy.
The company said the European patent number 2,247,954 is the counterpart to US patent number 7,867,775 and covers the use of VeriStrat for selection of head and neck cancer patients for treatment with targeted drugs.
VeriStrat is a serum proteomic test which facilitates physicians to guide therapy for patients with advanced lung cancer.
Biodesix CEO David Brunel said the expansion of their patent estate is an integral part of their global strategy to protect VeriStrat and their technology platform.
Biodesix also received notice from the PTO that two additional patent applications covering the use of VeriStrat for monitoring of head and neck, as well as colorectal cancer are expected to issue early in the first quarter of 2012.